P086 Identification of a Novel Immunometabolic Target and Agonist for PLXDC2 for Amelioration of DSS Colitis Model in Mice

S Abdurahiman,R Mosig,F Cataldi,S Vermeire,B Verstockt

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0216

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background PLXDC2 is expressed on the cell surface of macrophage, dendritic and specific mesenchymal and epithelial cells whose activation shifts cellular metabolism and reduces oxidative stress to rebalance the immune response and decrease inflammation. It’s role in IBD pathogenesis is unknown. PLXDC2 activation improves disease severity in rheumatoid arthritis models1, while loss of PLXDC2 exacerbates the severity of disease in DSS colitis2. PX-04 is a novel, first-in-class, orally active PLXDC2 agonist. Here, we report on the consequences of activating PLXDC2 using PX-04 in an acute DSS colitis model. Methods Mice were given DSS in drinking water for seven days to induce disruption of the epithelial layer. At project initiation, mice were 8 weeks of age and began once daily dosing with 20mg/kg of PX-04 24 hours after being placed on DSS. Mice were weighed and scored daily for 15 symptoms of disease (weight loss, diarrhea, rectal bleeding, rectal inflammation, pain, & overall behavior). Colons were collected and digested, and the resultant cellular suspensions were filtered to produce single cell suspensions. Colonic Lamina Propria Immune cells were isolated by Percoll gradient centrifugation. Cells were labeled with mixtures of extracellular (CD45, CD3, CD4, CD8, CD19, NK1.1, CD25, F4/80, CD11b, Gr1, CX3CR1, CD64) and intracellular (Tbet, RORγT, FOXP3, IFNγ, IL17, IL10, TNFα) antibodies in a sequential live staining in 96-well plates. Data was acquired using a FACS Celesta flow cytometer with FACSDiva software. Results Oral PX-04 treatment decreased the cumulative disease activity of mice challenged with DSS (FIG 1A). Immunologically, PX-04 affected both the adaptive and innate immune responses. First, PX-04 greatly decreased Th17 cells in the colon, while providing a slight increase to regulatory CD4+ T cells (FIG. 1C). A lower proportion of Natural Killer (NK) cells (FIG. 7D) produced IFNγ. Meanwhile, the proportion of TNF producing dendritic cells was decreased by PX-04 treatment. Conclusion Conclusion: PLXDC2 is expressed in cells relevant to IBD pathogenesis. PX-04, which binds to and activates PLXDC2, effectively decreases levels of effector T cells and myeloid cells, as well as overall disease severity in acute DSS colitis, warranting further investigation. 1Tubau-Juni et al. J Immunol 206(Supp) 2Tubau-Juni et al. Sci Rep 10(1)

gastroenterology & hepatology

What problem does this paper attempt to address?

The paper aims to explore the role of PLXDC2 in inflammatory bowel disease (IBD) and its efficacy as a potential therapeutic target. Specifically, researchers found that PLXDC2 is expressed on the surface of macrophages, dendritic cells, and certain stromal and epithelial cells. Activating these cells can alter their metabolic state, reduce oxidative stress, thereby rebalancing the immune response and reducing inflammation. Although PLXDC2 has shown effects in improving disease severity in rheumatoid arthritis models, the specific mechanisms in IBD are still unclear. Existing studies suggest that the loss of PLXDC2 exacerbates the condition in acute colitis mouse models.

To test this hypothesis, researchers used a novel oral PLXDC2 agonist named PX-04 in experiments with an acute dextran sulfate sodium (DSS)-induced colitis mouse model. The results showed that PX-04 significantly reduced the overall disease activity of DSS-induced colitis in mice and affected both adaptive and innate immune responses. Specifically, PX-04 reduced the number of Th17 cells, slightly increased the proportion of regulatory CD4+ T cells, and decreased the proportion of natural killer (NK) cells producing interferon-γ (IFNγ), while also reducing the proportion of dendritic cells producing tumor necrosis factor (TNF).

In summary, this study demonstrates the potential of PLXDC2 as a novel immunometabolic target in the treatment of IBD. PX-04, as the first agonist used to activate PLXDC2, showed good efficacy in the acute DSS colitis model, warranting further in-depth research.